Histogen Inc
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its prec… Read more
Histogen Inc (HSTO) - Total Liabilities
Latest total liabilities as of September 2023: $1.41 Million USD
Based on the latest financial reports, Histogen Inc (HSTO) has total liabilities worth $1.41 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Histogen Inc - Total Liabilities Trend (2013–2022)
This chart illustrates how Histogen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Histogen Inc Competitors by Total Liabilities
The table below lists competitors of Histogen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Active Energy Group PLC
PINK:ATGVF
|
USA | $916.13K |
|
Marr SpA
BE:M6Z
|
Germany | €982.19 Million |
|
SAPPORO HOLDINGS
MU:SBW
|
Germany | €484.64 Billion |
|
Chesnara
LSE:CSN
|
UK | GBX13.22 Billion |
|
Homebiogas Ltd
TA:HMGS
|
Israel | ILA2.20 Million |
|
Bytes Technology Ltd
LSE:BYIT
|
UK | GBX342.52 Million |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
USA | $1.93 Billion |
Liability Composition Analysis (2013–2022)
This chart breaks down Histogen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Histogen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Histogen Inc (2013–2022)
The table below shows the annual total liabilities of Histogen Inc from 2013 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $5.70 Million | -19.29% |
| 2021-12-31 | $7.06 Million | -12.85% |
| 2020-12-31 | $8.10 Million | -80.20% |
| 2019-12-31 | $40.91 Million | +91.13% |
| 2018-12-31 | $21.40 Million | -60.32% |
| 2017-12-31 | $53.94 Million | -10.89% |
| 2016-12-31 | $60.54 Million | +1067.08% |
| 2015-12-31 | $5.19 Million | -0.90% |
| 2014-12-31 | $5.23 Million | +37.12% |
| 2013-12-31 | $3.82 Million | -- |